A role for methotrexate in the management of non-infectious orbital inflammatory disease

被引:90
|
作者
Smith, JR [1 ]
Rosenbaum, JT [1 ]
机构
[1] Oregon Hlth Sci Univ, Casey Eye Inst, Portland, OR 97201 USA
关键词
D O I
10.1136/bjo.85.10.1220
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Aim-To evaluate the clinical usefulness of methotrexate for patients with noninfectious orbital inflammatory disease who fail to respond to systemic corticosteroids and/or orbital irradiation. Methods-The medical records of patients with non-infectious orbital inflammatory disease who were treated with methotrexate at Oregon Health Sciences University between June 1993 and June 2000 were examined. Methotrexate was administered at a median maximum dose of 20 mg per week (range 15-25 mg per week) in conjunction with folate supplementation. Patients were followed with regular ophthalmic examinations, as well as serum liver enzyme levels and blood cell counts. Clinical signs of regression of the orbital inflammation, visual acuity, dosage and duration of methotrexate therapy, requirement for concurrent corticosteroid administration, and adverse drug reactions were recorded. Results-The study cohort included 14 patients (24 eyes) with diagnoses including non-specific orbital inflammation (n=7), Tolosa-Hunt syndrome (n=1), thyroid orbitopathy (n=3), Wegener's granulomatosis (n=1), sarcoidosis (n=1), and Erdheim-Chester disease (n=1). In all cases, methotrexate was commenced as a corticosteroid sparing agent. 10 patients (71%) completed a 4 month therapeutic trial of methotrexate. Median duration of treatment for the nine (64%) patients who experienced clinical benefit was 25 months (range 10-47 months). Six responders were ultimately able to cease methotrexate, including the single patient who required concurrent long term corticosteroid therapy. Complications included fatigue, gastrointestinal disturbance, hair thinning and mild, reversible serum liver enzyme elevation. Two patients (14%) discontinued treatment because of adverse effects. Conclusion-Methotrexate is a well tolerated immunosuppressive medication which may benefit patients with recalcitrant non-infectious orbital inflammatory disease.
引用
收藏
页码:1220 / 1224
页数:5
相关论文
共 50 条
  • [1] Rituximab for treatment of non-infectious and non-malignant orbital inflammatory disease
    Ng, Caleb C.
    Sy, Aileen
    Cunningham, Emmett T., Jr.
    [J]. JOURNAL OF OPHTHALMIC INFLAMMATION AND INFECTION, 2021, 11 (01)
  • [2] Rituximab for treatment of non-infectious and non-malignant orbital inflammatory disease
    Caleb C. Ng
    Aileen Sy
    Emmett T. Cunningham
    [J]. Journal of Ophthalmic Inflammation and Infection, 11
  • [3] Non-infectious hypertrophic pachymeningitis associated with orbital inflammatory disease: a pooled analysis
    Ang, Terence
    Kundu, Naman
    Patel, Sandy
    Tong, Jessica Y.
    Selva, Dinesh
    [J]. ORBIT-THE INTERNATIONAL JOURNAL ON ORBITAL DISORDERS-OCULOPLASTIC AND LACRIMAL SURGERY, 2024,
  • [4] Non-infectious orbital vasculitides
    Perumal, B.
    Black, E. H.
    Levin, F.
    Servat, J. J.
    [J]. EYE, 2012, 26 (05) : 630 - 639
  • [5] Non-infectious orbital vasculitides
    B Perumal
    E H Black
    F Levin
    J J Servat
    [J]. Eye, 2012, 26 : 630 - 639
  • [6] Mycophenolate versus Methotrexate in Non-infectious Ocular Inflammatory Disease: A Systematic Review and Meta-Analysis
    Karam, Mohammad
    Alsaif, Abdulmalik
    Al-Naseem, Abdulrahman
    Hayre, Amrit
    Al Jabbouri, Abdurrahman
    Aldubaikhi, Ahmed
    Kahlar, Narvair
    Al-Mutairi, Salem
    [J]. OCULAR IMMUNOLOGY AND INFLAMMATION, 2023, 31 (03) : 613 - 620
  • [7] Anaphylatoxins and infectious and non-infectious inflammatory diseases
    Köhl, J
    [J]. MOLECULAR IMMUNOLOGY, 2001, 38 (2-3) : 175 - 187
  • [8] The role of biologic agents in the management of non-infectious uveitis
    Heo, Jangwon
    Sepah, Yasir J.
    Yohannan, Jithin
    Renner, Morgan
    Alchtar, Abeer
    Gregory, Anthony
    Shulman, Mathew
    Do, Diana V.
    Quan Dong Nguyen
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (08) : 995 - 1008
  • [9] Spectrum of non-inflammatory bowel disease and non-infectious colitis
    Ioannis E Koutroubakis
    [J]. World Journal of Gastroenterology, 2008, 14 (48) : 7277 - 7279
  • [10] METHOTREXATE RESPONSE IN PEDIATRIC NON-INFECTIOUS UVEITIS
    Angeles-Han, S.
    Cassedy, A.
    Hennard, T.
    Altaye, M.
    Brunner, H.
    Dosunmu, E.
    Grom, A.
    Henrickson, M.
    Huggins, J.
    Lopper, S.
    Lovell, D. J.
    Sisk, R.
    Ting, T.
    Kaufman, A.
    Utz, V.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 989 - 990